New cancer treatment could 'change the world' for newly diagnosed head and neck cancer patients by adding several years to their life
During a major phase III trial, pembrolizumab combined with standard treatment kept cancer at bay for an average of 60 months - five years - compared to the typical 30 months.
During a major phase III trial, pembrolizumab combined with standard treatment kept cancer at bay for an average of 60 months - five years - compared to the typical 30 months.
